Best-Value Biological Medicine: Eculizumab

The HSE-Medicines Management Programme (MMP) is undertaking a formal consultation phase as part of the process for the identification of best-value biological (BVB) medicines for eculizumab.

The MMP roadmap for the prescribing of best-value biological (BVB) medicines in the Irish healthcare setting (PDF, size 479.6 KB, 2 pages) outlines the criteria that will be considered by the MMP in identifying BVB medicines for eculizumab.

Submissions are invited from all relevant stakeholders, and should be emailed to mmp@hse.ie by 1pm on Wednesday 28 January 2026.